Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Cara Beahm"'
Autor:
Cezar Iliescu, Stephanie Pesant, Risto Kerkelä, Sergei P. Shevtsov, Luanda Grazette, Fred J. Clubb, Rinat Yacobi, Richard D. Patten, Brian Walters, Thomas Force, Cara Beahm, Robert N. Salomon, Joseph Alroy, Anthony Rosenzweig, Richard A. Van Etten, Jean-Bernard Durand
Publikováno v:
Nature Medicine. 12:908-916
Imatinib mesylate (Gleevec) is a small-molecule inhibitor of the fusion protein Bcr-Abl, the causal agent in chronic myelogenous leukemia. Here we report ten individuals who developed severe congestive heart failure while on imatinib and we show that
Autor:
Cara Beahm, Tammy F. Chu, David Kramer, Thomas Force, Ming-Hui Chen, Kathleen C. Woulfe, Jean-Bernard Durand, Ronald J. Vagnozzi, Risto Kerkelä
Publikováno v:
Clinical and translational science. 2(1)
Tyrosine kinase inhibitors (TKIs) are transforming the treatment of patients with malignancies. One such agent, sunitinib (Sutent, Pfizer, New York, NY, USA), has demonstrated activity against a variety of solid tumors. Sunitinib is “multitargeted,
Autor:
Bradley W. Doble, James R. Woodgett, Kathleen C. Woulfe, Thomas Force, Jonathan A. Epstein, Risto Kerkelä, Sarah Greytak, Jibin Zhou, Katrina MacAulay, Lisa Kockeritz, Cara Beahm, Gordon S. Huggins, Chinmay M. Trivedi
Based on extensive preclinical data, glycogen synthase kinase-3 (GSK-3) has been proposed to be a viable drug target for a wide variety of disease states, ranging from diabetes to bipolar disorder. Since these new drugs, which will be more powerful G
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6da305963d811e9887932e2a63570b1f
https://europepmc.org/articles/PMC2556242/
https://europepmc.org/articles/PMC2556242/